BSX · 10-Q · 2026Q3 · Full report

Products and Technology

BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 26 · Surprise 24

Boston Scientific attributed Cardiovascular growth to its coronary therapies franchise, led by the AGENT Drug-Coated Balloon, and, for the first nine months, to Electrophysiology led by the Farapulse Pulsed Field Ablation System. Endoscopy growth over the first nine months was led by the biliary franchise and AXIOS Stent and Delivery System. Neuromodulation growth was led by the Nalu Peripheral Nerve Stimulation System, Intracept Intraosseous Nerve Ablation System and deep brain stimulation franchise; Neuromodulation sales growth was 13.1% in the quarter and 14.3% for the first nine months.

Key facts

• Boston Scientific's R&D expenses increased $6 million, or 1%, in the third quarter of 2026 and $106 million, or 7%, in the first nine months, driven primarily by investments to maintain future product-sales pipelines. source
• Boston Scientific's nine-month 2026 Endoscopy sales growth was driven primarily by its biliary franchise, led by the AXIOS Stent and Delivery System, offset by cybersecurity-related operational disruptions. source
• Boston Scientific's Neuromodulation sales growth in the third quarter and first nine months of 2026 was driven by its pain portfolio, led by the Nalu Peripheral Nerve Stimulation System and Intracept Intraosseous Nerve Ablation System, and its deep brain stimulation franchise. source
• Boston Scientific's Cardiovascular sales growth was driven by its coronary therapies franchise, led by the AGENT Drug-Coated Balloon; nine-month growth was also led by Electrophysiology and the Farapulse Pulsed Field Ablation System, offset by cybersecurity disruptions. source